, Papers of special note have been highlighted as either of interest (?) or of considerable interest (??) to readers. 1. WHO |Cancer

A. Brewster, G. Hortobagyi, and K. Broglio, Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy, JNCI Journal of the National Cancer Institute, vol.365, issue.9472, pp.1179-1183, 2008.
DOI : 10.1016/S0140-6736(05)66544-0

C. Twelves, M. Jove, and A. Gombos, Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer, Critical Reviews in Oncology/Hematology, vol.100, pp.74-87, 2016.
DOI : 10.1016/j.critrevonc.2016.01.021

A. Kruczynski, J. Barret, and C. Etiévant, Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid, Biochemical Pharmacology, vol.55, issue.5, pp.635-648, 1998.
DOI : 10.1016/S0006-2952(97)00505-4

A. Kruczynski and B. Hill, Vinflunine, the latest Vinca alkaloid in clinical development, Critical Reviews in Oncology/Hematology, vol.40, issue.2, pp.159-173, 2001.
DOI : 10.1016/S1040-8428(01)00183-4

A. Kruczynski, M. Poli, and R. Dossi, Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development, European Journal of Cancer, vol.42, issue.16, pp.2821-2832, 2006.
DOI : 10.1016/j.ejca.2006.06.019

C. Etievant, J. Barret, and A. Kruczynski, 20?- difluoro-3?,4?-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro, Invest New Drugs, vol.2016, pp.3-17, 1998.

J. Bennouna, J. Delord, and M. Campone, Vinflunine: A New Microtubule Inhibitor Agent, Clinical Cancer Research, vol.14, issue.6, pp.1625-1632, 2008.
DOI : 10.1158/1078-0432.CCR-07-2219

X. Zhao, J. Zhong, and X. Liu, CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes, Acta Pharmacologica Sinica, vol.270, issue.1, pp.118-124, 2007.
DOI : 10.1016/j.jpba.2006.01.005

J. Bennouna, P. Fumoleau, and A. J. , Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours, Annals of Oncology, vol.14, issue.4
DOI : 10.1093/annonc/mdg174

, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.14, pp.630-637, 2003.

M. Campone, H. Cortes-funes, and D. Vorobiof, Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy, British Journal of Cancer, vol.66, issue.9
DOI : 10.1023/A:1010679127390

, Br J Cancer, vol.95, pp.1161-1166, 2006.

M. Blasinska-morawiec, N. Tubiana-mathieu, and R. Fougeray, Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer, The Breast, vol.22, issue.1, pp.58-63, 2013.
DOI : 10.1016/j.breast.2012.10.007

P. Fumoleau, H. Cortés-funes, and A. Taleb, Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of Metastatic Breast Cancer After Failure of Anthracycline-/Taxane-Based Chemotherapy, American Journal of Clinical Oncology, vol.32, issue.4, pp.375-380, 2009.
DOI : 10.1097/COC.0b013e31818f2d2f

P. Fumoleau, R. Largillier, and C. Clippe, Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer, European Journal of Cancer, vol.40, issue.4, pp.536-542, 1990.
DOI : 10.1016/j.ejca.2003.11.007

M. Campone, N. Isambert, and E. Bourbouloux, A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes, Cancer Chemotherapy and Pharmacology, vol.32, issue.6, pp.871-879, 2012.
DOI : 10.1097/FTD.0b013e3181f6010c

K. Zaman, X. Durando, and J. Baurain, A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer, Breast Cancer Research and Treatment, vol.354, issue.Suppl 3, pp.689-696, 2011.
DOI : 10.1056/NEJMoa054504

S. Chan, M. Campone, and A. Santoro, A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer, Cancer Chemotherapy and Pharmacology, vol.127, issue.10, pp.903-910, 2014.
DOI : 10.1007/s10549-011-1446-x

H. Sanoff, J. Davies, and C. Walko, A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors, Investigational New Drugs, vol.109, issue.9, pp.978-983, 2011.
DOI : 10.1002/cncr.22616

R. Paridaens, O. Rixe, and M. Pinel, A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer, Cancer Chemotherapy and Pharmacology, vol.56, issue.24, pp.503-511, 2012.
DOI : 10.1007/s00280-005-1026-z

D. Yardley, M. Mccleod, and F. Schreiber, A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer, Cancer Investigation, vol.25, issue.9, pp.925-931, 2010.
DOI : 10.1080/01621459.1958.10501452

, A study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with advanced breast cancer Available from: https://clinicaltrials.gov/ct2/show, p.5, 2016.

, Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the first-line treatment of anthracycline pretreated advanced breast cancer, J Clin Oncol, pp.129692-144, 2009.

, Trial of vinflunine plus capecitabine in advanced breast cancer Available from: https://clinicaltrials.gov/ct2/ show, 2016.

, Phase III study of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer Available from: https://clinicaltrials.gov/ct2/show, p.4, 2016.

, Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: a phase III study versus capecitabine, J Clin Oncol, pp.129586-144, 2016.

, ? This phase III study shows an improvement in progression-free survival with vinflunine?capecitabine combination

M. Martin, Y. Demidchik, and I. Bondarenko, 358PDVINFLUNINE (VFL) PLUS CAPECITABINE (CAPE) FOR ADVANCED BREAST CANCER (ABC) PREVIOUSLY TREATED WITH OR RESISTANT TO ANTHRACYCLINE AND RESISTANT TO TAXANE : A PHASE 3 STUDY VERSUS CAPECITABINE, Annals of Oncology, vol.25, issue.suppl_4, pp.119-119, 2014.
DOI : 10.1093/annonc/mdu329.8
URL : https://academic.oup.com/annonc/article-pdf/25/suppl_4/iv119/9689931/mdu329.8.pdf

, ? This phase III study shows an improvement in progression-free survival with vinflunine?capecitabine combination

, Trial of vinflunine versus alkylating agent in metastatic breast cancer Available from: https://clinicaltrials.gov/ct2/ show, p.6, 2016.

, A randomized phase III study of vinflunine versus an alkylating agent of physician's choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid Available from, J Clin Oncol, pp.147029-156, 2009.

, ? This phase III study does not show difference in overall survival with vinflunine

J. Cortes, O. Shaughnessy, J. Loesch, and D. , Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, The Lancet, vol.377, issue.9769, pp.914-923, 2011.
DOI : 10.1016/S0140-6736(11)60070-6

J. Baselga, M. Campone, and M. Piccart, Everolimus in Postmenopausal Hormone-Receptor???Positive Advanced Breast Cancer, New England Journal of Medicine, vol.366, issue.6, pp.520-529, 2012.
DOI : 10.1056/NEJMoa1109653

M. Cristofanilli, N. Turner, and I. Bondarenko, Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptorpositive , HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre , double-blind, phase 3 randomised controlled trial, Lancet Oncol, vol.15, pp.10-1016, 2016.

J. Bellmunt, C. Théodore, and T. Demkov, Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract, Journal of Clinical Oncology, vol.27, issue.27, pp.4454-4461, 2009.
DOI : 10.1200/JCO.2008.20.5534